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Abstract 
Rapid identification of infectious disease pathogens such as foot-and-mouth disease virus (FMDV) during new 
outbreaks of disease is of fundamental importance in disease control. SpectroSensTM optical microchip sensors 
demonstrating rapid, label-free detection of FMDV are presented; these contain multiple high-precision planar Bragg 
gratings and function as low-cost, robust refractive-index sensors. Sensor selectivity to FMDV is imparted by 
functionalising the top-surface of specific sensing channels with anti-FMDV monoclonal antibodies (mAbs). 
Selective binding of cognate antigens within the test sample to surface-immobilised FMDV mAbs results in localised 
changes in refractive index within specific sensing channels; these antibody-antigen interactions manifest as increases 
in wavelength of light reflected from the multi-channel sensor chip (light is coupled into and out of the chip via 
optical fibres). Selective identification of FMDV within minutes of sample introduction has been demonstrated by 
referenced measurement of changes in sensor reflected wavelength from anti-FMDV channels against sensor 
controls; simplified ‘snap-shot’ assay data are displayed in the form of a simple yes/no readout using a robust, hand-
portable device, with further semi-quantitative information available to the ‘super-user’. The characteristics of the 
SpectroSensTM multiplexed detection platform highlight its potential for in-field detection of foot-and-mouth disease 
and prospective expansion into diagnoses of other infectious veterinary diseases. 
© 2011 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of the Institute of 
Bio-Sensing Technologies, UWE Bristol.  
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1. Introduction 
Foot-and-mouth disease (FMD) is a highly infectious viral disease that affects domesticated livestock 
including cattle, pigs, sheep and goats, and is considered to be the most economically devastating 
livestock disease worldwide. A total of 2,030 cases of FMD were confirmed in the United Kingdom 
during an epidemic disease outbreak in 2001 [1]; in an ultimately successful attempt at arresting the 
disease in October 2001, approximately 6 million livestock were culled, by which time the crisis was 
estimated to have cost £8 billion [2].  
Definitive identification of FMD virus (FMDV) relies on virus isolation by cell culture, coupled with 
immunochemical and nucleic acid-based techniques; this approach is time-consuming, laborious and 
confined to specialised laboratories with expensive readout instrumentation [3,4,5]. Rapid, in-field 
detection of infectious disease pathogens in livestock is imperative if future epidemics are to be prevented 
by expediting suitable control measures. Recent efforts in rapid FMDV detection have focused on the 
development of rapid chromatographic strip tests or lateral flow devices (LFDs) based on disease-specific 
or serotype-specific mAbs [6,7] and PCR-based techniques [8,9]; however, whilst progressing towards in-
field analyses, many of these devices are associated with limitations (e.g. sample preparation issues, test 
reliability) that hinder their widespread implementation. Over the last few decades, immuno-biosensors 
have received escalating interest as powerful and versatile detection tools for applications requiring on-
site analyses, primarily due to their speed of analysis and simplicity of operation [10,11,12,13]. 
Recently, a novel immuno-biosensor system based on optical microchip sensors (SpectroSensTM), 
leveraging integrated optical circuits from the telecommunications industry, has been reported in its 
capacity for biological agent detection [14,15,16]. SpectroSensTM optical microchip sensors comprise 
multiple high-precision planar Bragg gratings fabricated within spatially-separated waveguide channels, 
using the direct grating writing method described by Emmerson et al., [17]. Bragg gratings act as sensitive 
wavelength filters, reflecting light at precisely-defined wavelengths governed by the Bragg condition:  
λmax = 2 Λ neff             (1) 

where λmax is the wavelength of light at which maximum reflectivity occurs, Λ defines the grating 
period and neff is the average refractive index of the waveguide’s composite structure. Hence, sensor 
reflected wavelengths are influenced by the local environment within the vicinity of specific gratings. 
Functionalisation of individual waveguide channels with target-selective antibodies confers localised 
sensitivity to specific biological agents; interactions between target antigens within the test sample and 
respective surface-immobilised antibodies are associated with localised changes in refractive index, which 
manifest as changes in sensor reflected wavelength from specific sensing channels (Figure 1). 
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Fig. 1. Schematic Illustration of the operating principle of SpectroSensTM biological detection. a) Target bio-hazards in the liquid 
sample are directly captured by specific antibodies immobilised on individual sensing channels within the SpectroSensTM optical 
microchip sensor; (b) changes in sensor reflected wavelength associated with selective antigen binding are captured by the 
SpectroSensTM detector. 
This communication describes the use of SpectroSensTM optical microchip sensors, functionalised with 
appropriate antibodies, for the rapid detection of FMDV; further technological improvements to the 
SpectroSensTM readout instrumentation and consumable packaging, culminating in a robust, hand-portable 
device with low-cost consumables, are also described.  
2. Results and discussion 
SpectroSensTM optical microchip sensor technology is the result of the multi-disciplinary integration of 
the fields of optoelectronics, biochemistry and microfluidics. The purpose of this work was to evaluate the 
use of SpectroSensTM technology for rapid detection of the aetiological agent of FMD.  
2.1. SpectroSensTM consumable 
Several configurations of SpectroSensTM optical microchip sensors have been fabricated using the 
direct grating writing method, examples of which are described in Sparrow et al., [18]. The multichannel 
chips used in this particular study comprised 4 independent optical sensing channels, two of which were 
functionalised with mAb BF8 raised against FMDV type O1 Manisa (produced at IAH) [19] for use as 
test channels, while the other two were functionalised with non-immune rabbit IgG antibodies as sensor 
controls to enable referenced sample measurements. Each 4-channel SpectroSensTM chip was housed 
within an easy-to-use, disposable cartridge for sample testing (Figure 2).  
Fig. 2. Schematic illustration of the SpectroSensTM consumable used for FMDV detection. A 4-channel SpectroSensTM optical 
microchip sensor is housed within a disposable, easy-to-use test cartridge. 
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Surface-immobilisation of the detection antibodies, whilst retaining optimal antigen recognition 
capabilities, is critical to the performance of the biosensor. Functionalisation of SpectroSensTM microchips 
was achieved by exploiting the well-documented self-assembly of organosilanes on metal oxide surfaces 
[20]. Anti-FMDV antibodies were oriented via affinity-interaction with Protein G, which was attached 
covalently to aminosilanised sensor surfaces using glutaraldehyde cross-linking. 
2.2. FMDV detection 
FMDV antibody-functionalised SpectroSensTM consumables were equilibrated in PBS running buffer 
at a flow rate of 5 μl/min in preparation for sample testing; these were used to determine the presence of 
FMDV by exposure to a PBS buffer sample spiked with inactivated FMDV serotype O1 antigen (stock 
sample supplied by IAH) [21] at an estimated concentration of 107 virions/ml. The sensorgram presented 
in Figure 3 illustrates the real-time sensor output from a SpectroSensTM laboratory system [16] in response 
to the FMDV-containing test sample. The isolated changes in sensor reflected wavelength within anti-
FMDV-functionalised test channels, in comparison with negligible changes in control channels, following 
antigen exposure, demonstrate specific detection of FMDV. The initial increases in sensor reflected 
wavelength visualised in all channels are associated with the higher bulk refractive index of the antigen-
containing sample, relative to that of the PBS equilibration buffer, as evidenced by the subsequent 
reduction in reflected wavelength upon returning to PBS buffer, post-sample incubation. The inset 
displays the actual changes in optical spectra before and after FMD detection from a single (a) test 
channel and (b) control channel. Whilst the sample-incubation period during this particular assay was 
relatively long (30 minutes), the real-time sensorgram clearly indicates that significant discrimination 
between sensor responses from test and control channels occur within the first 10 minutes of sample 
introduction.  
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Fig. 3. Real-time SpectroSensTM sensorgram demonstrating specific detection of FMDV.  FMDV antibody-functionalised 
SpectroSensTM consumables were exposed to inactivated FMDV (~107 virions/ml) in PBS-T at a flow rate of 5 μl/min. Binding 
interactions across all 4 sensor channels were monitored for ~30 min before washing with PBS-T running buffer: (-) anti-FMDV 
channels, (--) control channels. Inset: overlaid optical spectra before and after FMDV exposure (a) anti-FMDV channel, (b) control 
channel.
2.3. Portable technology demonstrator 
Technological improvements to the SpectroSensTM readout instrumentation have enabled the 
development of a robust, hand-portable technology demonstrator with the potential for use in-the-field 
(Figure 4). FMDV-antibody-functionalised SpectroSensTM consumables were plugged into this portable 
device to enable the fluidic connections and optical readout. The assay for FMDV detection was 
performed as follows: a sample of PBS buffer was injected into the device and a background measurement 
taken using the touch-screen user-interface; subsequently, the FMDV test sample (~107 virions/ml) was 
injected into the device, left to equilibrate for 3-5 minutes and finally followed through with more PBS 
buffer prior to obtaining the sample measurement. The data output from the portable device constituted a 
simple yes/no (red/green) readout based on differences in magnitude of sensor reflected wavelength 
between test and control channels above a pre-determined threshold, calculated from temporally quantised 
data obtained pre- and post- sample exposure. The assay for FMDV detection was conducted in triplicate 
on the portable device using the same test sample with 3 independently-prepared consumables. On each 
occasion the readout displayed on the touch-screen user interface indicated positive (red) identification of 
FMDV (Figure 4a), as significant discrimination of the sensor response between test and control channels 
was achieved after a 3-5 minute sample incubation period. An ‘advanced’ function enabled retrieval of 
further semi-quantitative information, which indicated the magnitude of change in reflected wavelength 
(control-subtracted) from individual sensor channels (Figure 4b).  
Fig. 4. SpectroSensTM portable biosensor system illustrating the touch-screen user-interface. (a) simple yes/no readout, (b) advanced 
semi-quantitative readout following successful FMDV detection. 
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Fig. 5. Bar chart displaying SpectroSensTM responses associated with FMDV detection. Processed data from the portable biosensor 
representing changes in sensor reflected wavelength following FMDV detection within anti-FMDV channels (red) and control 
channels (green) using 3 independent consumables (Tests 1-3). 
Data extracted from the portable device representing the changes in sensor reflected wavelength 
associated with FMDV detection during each of the triplicate assays are presented in the bar chart 
displayed in Figure 5. For all assays (Tests 1-3), the sensor responses within anti-FMDV channels (Ch 1 
and Ch 2) are significantly greater (>3x mean control response) than those within control channels (Ch 
and & Ch 4); the mean shift (n=3) in sensor reflected wavelength (control-subtracted) associated with 
FMDV capture is approximately 0.09 nm, though both intra- and inter-assay variations in the magnitude 
of sensor responses can be observed. These preliminary performance characteristics highlight the potential 
of this portable biodetector for rapid in-field FMDV detection.  
Ongoing work is focused on investigating various performance-enhancement methodologies aimed at 
investigating the sensitivity and improving the reproducibility of the sensor responses, as well as further 
miniaturisation of the biodetector instrument into a hand-held device. 
3. Conclusion 
Preliminary data demonstrating the use of SpectroSensTM optical microchip sensors for the rapid 
detection of foot-and-mouth disease virus (FMDV) by exploiting the specific FMDV antibody-antigen 
interaction has been presented; the consumable design is easily modified for the detection of additional 
biological pathogens by functionalisation of individual sensing channels with different target-specific 
antibodies. A robust, hand-portable prototype readout device has been developed as a technology 
demonstrator, highlighting the potential for rapid, on-site multiplexed pathogen detection. Further work 
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comprising larger-scale testing with field samples is necessary to demonstrate ultimate application in-the-
field; if successful, this device has the potential to have a substantial impact on epidemic prevention, by 
enabling first responders to identify infectious diseases and implement appropriate control measures 
much earlier than is currently possible with laboratory-based techniques. 
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